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The Use of the Reducing Agent N-(2-Mercaptopropionyl)glycine to Detoxify 
Oxidized Lipids in Atherosclerotic Lesions 
Nason P. Schooler 
December 1, 2008 
The leading cause of death in the United States is cardiovascular disease, a result 
of atherosclerosis. The reducing agent N-(2-Mercaptopropionyl)glycine (MPG) as been 
found to be an effective antioxidant therapy in a number of conditions, and our 
hypothesis is that it will be an effective agent in the detoxification of oxidized lipids in 
atherosclerosis. Our results indicate some protective effect, along with some toxicity at 
high doses, with refinement of the experimental model necessary before results can be 
conclusive. Nevertheless, antioxidant and aldehyde-quenching agents in general have 
been shown to be of benefit in the detoxification of oxidized lipids, and MPG is still 
therefore a good candidate. Since this is yet another mechanism used to combat the 
disease, we hypothesize that such reducing agents will complement other therapies quite 
effectively, providing an even more effective means of preventing the onset, as well as 
reversing the progression of atherosclerosis. 
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INTRODUCTION 
Cardiovascular disease (CYO) is the leading cause of death in the US, the major 
contributor being coronary artery disease brought on by the onset of Atherosclerosis.4 
Atherosclerosis is the pathology behind the two major components of cardiovascular 
disease; vascular disease leading to stroke, and coronary artery disease leading to heart 
attacks. The main characteristic of an atherosclerotic lesion is the deposition of 
cholesterol in medium to large arteries. In these critical vessels, the cholesterol deposits 
can grow over time, until the blood now is hindered by the resulting occluded lumen, and 
heart attack and stroke result when the flow is completely blocked. Usually an actual 
rupture of a mature atherosclerotic plaque is the cause of sudden-onset heart attack or 
stroke. 5 
One of the most important factors influencing the development of atherosclerosis 
is the amount of cholesterol in circulation. This relationship between cholesterol and the 
development of atherosclerosis was recognized early on due to the genetic disorder 
Familial hypercholesterolemia. Heterozygote patients with this trait have a reduced 
number of LDL (low density lipoprotein - a common form of cholesterol packaged for 
transport in the bloodstream) receptors, and homozygous individuals have no LDL 
receptors. This is devastating particularly in the case of hepatic cells, which are 
responsible for removing cholesterol from the bloodstream. Thus, these individuals have 
high levels of circulating cholesterol, and correspondingly short lifespan, due to early-
onset atherosclerosis and subsequent cardiovascular disease. Furthermore, cholesterol-
lowering therapy has been found to greatly alleviate, and in some cases reverse the 
progression of atherosclerosis. Key among these are the statins - a group of compounds 
targeting the key regulatory enzyme in cholesterol synthesis: HMG-CoA reductase.6 
The Anatomy of a Blood Vessel 
Before we begin our discussion of the features and development of atherosclerotic 
lesions, it will help to describe the basic features of a normal artery. Figure 1 depicts the 
three principal layers which surround the arterial lumen. The intima consists of a 
monolayer of vascular endothelial cells on a second layer of mostly smooth muscle cells 
in a substrate of extracellular matrix . The media is made up of further layers of smooth 
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Figure 1 - The layers of tissue in an artery. The intima is closest to the 
lumen, while the Adventitia makes up the outer surface of the vessel. 
muscle cells, and the adventitia, consisting 
of collagen, fibroblasts , smooth muscle cells 
and elastin. Thin layers of elastin also 
separate the other layers, making up the 
internal and external elastic laminas. 
The Development of Atherosclerotic Lesions 
Despite the fact that the relationship between cholesterol in circulation, 
cholesterol deposits in arteries and atherosclerosis is well known, the fundamental 
genesis of these deposits has not been definitively identified. What is known for certain 
is that fatty streaks - small deposits of cholesterol in the intima - begin forming at an 
early age in the arteries of most denizens of developed societies. Preceding the 
appearance of these fatty streaks, is a thickening of the intima - termed type I lesions, 
these instances of thickening are thought to be an adaptive response to shear stresses 
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along the vessel wall and to tensile stresses against the wall. They are denoted as areas of 
eccentric thickening, as opposed to uniform thickening of the intima, called diffuse 
thickening, which does not directly correlate with atherosclerosis. While atherosclerotic 
lesions form at these sites, such areas of eccentric thickening occur whether or not 
atherosclerosis is present. The same stresses that result in eccentric thickening due to 
irregularities in the fluid flow also 
apparently contribute to cholesterol 
deposition in the intima, if serum 
cholesterol levels are high enough. 
Thus lesions form earlier at these 
locations than elsewhere in the arteries, 
and they are therefore associated with 
the initial appearance of fatty streaks, 
and subsequently the classic locations 
of advanced lesions.7 
Figure 2 shows the six 
morphological stages3 recognized as 
making up the classic development of an 
CoI'OlJary artery at 
l~i(Jn ·pron~ locatioo 
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Figure 2 - The six types of lesions in the progression of atherosclerosis. 
(From Stary et al ' ) 
atherosclerotic lesion. Following the adaptive thickening of the intimal smooth muscle 
region, There is an increase in the concentration of deposited plasma components. 
Proteins, HDL and LDL, along with most plasma constituents, deposit within the intima 
throughout the arteries in proportion to their concentrations in the bloodstream and their 
molecular weights. In regions of eccentric thickening, however, macrophages, LDL, and 
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the other plasma components are more concentrated. Since the endothelial layer directly 
adjacent to the arterial lumen is very amenable to such deposition, and since a large 
contributor seems to be the natural fluid flow in the lumen, it naturally follows that areas 
which thicken in response to excess tensile stress will accumulate additional material as a 
result of such stress. Thus, in these areas of eccentric thickening in normal healthy 
arteries the seeds of atherosclerosis are sown. The essential players are there - excess 
cholesterol in the form of LDL and macrophages to take them up and form foam cells. 
The current predominant view is that accumulation ofLDL leads to inflammation, thus 
initiating the onset of atherosclerosis. 8 The oxidization of LDL and the subsequent 
involvement of inflammation and macrophages in foam cell formation are key factors 
determining whether a fatty streak will remain benign, or develop into more advanced 
types of atherosclerotic lesions. Such oxidization can be the target for a variety of 
different interventions, which will be discussed below. 
Type II lesions are characterized by the formation of fatty streaks made up of 
macrophages that have taken up excessive amounts of lipids (foam cells). Fatty streaks 
are not inherently pathologic, and may never tum into type III lesions, or they may even 
regress on their own. In fact, each of the six types of lesions represent inherently stable 
entities which may remain unchanged for long periods of time, or may continue on to 
become more advanced lesions.9 In the event that the fatty streaks continue to grow due 
to the accumulation of foam cells, type III lesions become evident. These are 
characterized by the appearance of extracellular lipid patches, which are the result of 
macrophage necrosis, and can readily accumulate by the age of 10 years. By the mid 30's 
they can account for one third of the surface area of the aorta. 10 
4 
Type IV lesions are considered full atheromas, conisisting of a large, contiguous 
area of extracellular lipids within the intima. Eventually, these areas can develop a hard, 
fibrous cap, at which point they are type V fibroatheroma lesions. Such lesion caps form 
mostly in the mid 30's to mid 40's, the vessels involved being predominantly abdominal 
aorta, coronary and carotid arteries. The main distinguishing factor between types IV 
and V is that of new structural fibrous material forming prominent connective tissue that 
was not present before. This tissue can be extensive, composed of several layers of 
lesions that form in a step-by-step fashion. Following the formation of an initial type V 
lesion, the flow geometry may change significantly, resulting in new deposition of tissue 
in a nearby, partially overlying area. This process can occur repeatedly, together with 
multiple thrombotic events and micro-hemorrhages in capillaries throughout the lesion, 
resulting in an irregularly stacked conglomeration of overlapping extracellular lipid cores 
separated by fibrous walls. By the time a lesion has reached type V, the original structure 
of the vessel has become significantly altered, resulting in a significant rearrangement of 
smooth muscle and endothelial cells, as well as rearrangement and formation of new 
areas of connective tissue. 3 
The most devastating pathologies arise from Type VI lesions, which arise when 
the shoulder region between the fibrous cap and the normal artery wall ruptures. Type VI 
lesions often contain evidence of previous fissuring in this area which has subsequently 
been patched over. At this point, the lesion is in danger of significant rupture and 
resulting thrombosis and occlusion of the artery at any time. 
The goal of preventive measures and even therapy is to intervene before lesions 
progress to this final stage. As would be naturally expected, earlier is better, and simple 
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modifications of the diet can result in complete reversion of type I, II and III lesions.9 
One of the earliest contributing factors in the development of foam cells is the appearance 
of oxidized lipids. Thus much research has been done to elucidate the underpinnings of 
this process, as well as where lipids are oxidized, and how the deleterious interaction with 
macrophages takes place. II 
The Role of Oxidized Lipids 
LDL has not been found to be an effective contributor to atherosclerosis in its 
normal state. Macrophages have been found to be quite reluctant to take up normal LDL. 
However, the LDL can become modified into a form that is highly atherogenic. Once 
LDL is oxidized, macrophages take it up approximately 40 times faster than normal LDL 
- and by a different class of receptors, called scavenger receptors. 12 While acetylation 
was carried out in initial in vitro experiments 13 to demonstrate this rapid uptake, this 
modification is not involved in vivo. Oxidative modification ofLDL does happen in the 





Figure 3 - The Oxidative Modification Process 
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LOL trapped in the intima becomes oxidized by vascular smooth muscle celis, endothelial celts and 
macrophages. A. This attracts more macrophages due to thei r chemotactic attraction to oxidized 
lipids. B. Monocytes are also prevented from leaving the intimal space. C. Nondegradable 
oxidized lipids accumulate in the Iysosomes of macrophag8s, which become foam cells. D. 
Endothelial cells also become injured and dysfunctional due to the presence of oxidized LDL. E. 
Accumulation of indigestible lipids in foam cells eventually leads to apoptosis and necrosis. (From 
Diaz et a.)' 
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up such LDL as readily as the 
acetylated version. 14 
Furthermore, oxidized LDL 
has been found to contribute 
to atherogenesis by its 
cytotoxicity to both 
endothelial cells and 
macrophages, by preventing 
macrophages from leaving 
the intima, and by aiding the attraction of circulating monocytes into the intima in the 
first place. 15 The role of oxidization of LDL in the development of atherosclerosis is 
summarized in Figure 3. 
When LDL is trapped in the intima and becomes oxidized by surrounding cells, 
the lysine residues of apolipoprotein-B-l 00 (one of the protein components of LDL) 
become more negatively charged. Haberland et al. have demonstrated that such 
malondialdehyde-induced modifications result in crosslinks which make the molecule 
amenable to scavenger-receptor uptake,16 eventually leading to the formation of foam 
cells. I? LDL can also be oxidatively modified independently of apolipoprotein-B-lOO. 
Such minimally modified LDL induces the production of monocyte chemotactic proteins 
in endothelial cells and also smooth muscle cells18, and overall inducing a pro-
inflammatory response in the tissue. 19 Without the necessary chemotaxis receptor, the 
macrophages of mice do not respond accordingly, and the mice have been found to be 
resistant to atherosclerosis.2o Monocytes and T-lymphocytes are also highly chemotactic 
in response to more heavily oxidized LDL21 (termed oxLDL), which also stimulates the 
production of auto-antibodies and immune complexes which facilitate macrophage 
ingestion ofLDL.22 Inflammation can also promote further oxidation ofLDL, thus 
expanding the lesion. 
Detoxification of Oxidized Lipids to Treat Atherosclerosis 
Since oxidation of LDL has been found to be quite deleterious and inherently 
foundational in the etiology of atherosclerosis, the search for effective methods to 
detoxify this substance has been and continues to be a major field of study.23 
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Current Therapies Using Antioxidants and Reducing Agents 
Vitamin E has been one of the most thoroughly investigated antioxidant therapies 
for atherosclerosis. While a number of small clinical trials have shown promising results, 
all large-scale clinical trials have shown no beneficial effect of vitamin E in the treatment 
of heart disease.24 In several animal models, and in certain special conditions, such as 
12/15-lypoxygenase gene inhibition, vitamin E has been shown to be quite beneficial in 
this regard.25 It seems that in certain groups, for instance those in which oxidative stress 
is a system-wide pathology, such antioxidant administration can be quite beneficial. 
Overall, vitamin E has been proven to be anti-oxidant or pro-oxidant or even neutral in 
atherogenesis, depending on myriad other factors. 26 
Other antioxidants which have been assayed for therapeutic intervention in 
atherogenesis include Glutathione27, Probucol and several analogs, individual 
polyphenols and mixtures of polyphenols, and combination therapy using vitamin E in 
conjunction with Selenium, vitamin A, or vitamin C.23 The role of human alto-keto-
reductase in protection against toxic aldehydes has also been examined,28 with an eye 
towards potential therapies involving similar adehyde reduction. Several types of 
aldehyde groups resulting from lipid peroxidation have been lumped together into the 
category of reactive carbonyl species (RCS). These include a,p-unsaturated aldehydes, 
di-aldehydes, and keto-aldehydes. Since RCS are widely prevalent in atherosclerotic 
lesions despite the presence of large amounts of antioxidants such as vitamins C and E in 
the vessel wall, an alternative strategy has been developed to detoxify them - namely, the 
use of agents which sequester and thus nullify carbonyls directly.29 These sacrificial 
nucleophiles directly attack and quench aldehyde groups, rendering RCS unable to 
damage other biomolecules.30,31 
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One particularly promising subset of these aldehyde quenching agents includes 
compounds containing a reactive thiol group. Examples include N-acetyl cysteine (NAC) 
and several analogs,32 as well as other compounds containing cysteine such as s-allyl 
cysteine, s-ethyl cysteine, s-methyl cysteine, and s-propyl cysteine.33 Also worthy of 
note, are combination therapies involving thiol-containing compounds, such as the 
combination ofN-acetyl cysteine and taurine,34 Of particular interest is the thiol-
Figure 4 - Penicillamine structure. The 
sulfhydril (thiol) group readily reacts with 
aldehydes, forming harmless thiazolidine 
derivatives. 
(From PubChem) 
containing small molecule compound D-Penicillamine 
(3,3-dimethyl-D-cysteine, see Figure 4), which was 
identified using a new screening process for aldehyde-
quenching agents developed by Wondrak and colleagues 
at the University of Arizona Tucson.l D-Penicillamine 
reacts with aldehyde groups to form benign thiazolidine 
derivatives, which are easily cleared from the system. This reaction is shown in Figure 5. 
The nucleophilic thiol group attacks the carbonyl carbon, freeing the oxygen as water and 
forming a covalent linkage at the former site of the aldehyde. Penicillamine is used 
therapeutically to treat a variety of pathologies, including rheumatoid arthritis (as a 




Figure 5 - Penicillamine aldehyde quenching reaction. The sulfhydril (th iol) group readily reacts with aldehydes, forming harmless thiazolidine 
derivatives. (From Wondrak et aL ' ) 
secondary medication), metal ion intoxication, cystinuria and Wilson's disease (copper 
storage disease) . 35 
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Another similar small-molecule compound containing such a reactive thiol group 
is N-(2-Mercaptopropionyl)glycine (MPG), which is also known by the names Acadione, 
Capen, Captimer, Epatiol, Meprin (detoxicant), Mucolysin, Sutilan, Thiola, 
Thiolpropionamidoacetic acid, Thiopronin, Thiopronine, Thiosol, Tioglis, Tiopronin, and 
Vincol. MPG is used to treat cystinuria,36 arthritis/ 7 a variety of drug toxicities 
associated with damaging carbonyls and reactive oxygen species (ROS)38,39, and also 
demonstrates significant protection against ischemialreperfusion injury.4o It is also used 
to scavenge ROS produced by ionizing radiation,41 
as well as radiation-produced lipid peroxidation.42 
Hypothesis 
Such protective effects against lipid 
peroxidation, together with the similar structure and 
function to D-Penicillamine, an already proven 
HyH~O 
11" IN ~1 o · 
Figure 6· MPG structure. The sulfhydril (!hiol) group 
readily reacts with aldehydes, forming harmless 
thiazolidine derivatives. 
(From PubChem) 
aldehyde quencher, have led to the hypothesis that MPG may offer significant aldehyde 
quenching in atherosclerotic lesions and thus protection against carbonyl toxicity in 
oxidized LDL. 
Proposed Mechanism 
MPG has been found to be a very effective free radical scavenger, and also iron 
chelation and glutathione sparing have also been proposed as mechanisms behind the 
protective effects conferred by MPG.43 The susceptibility of its reactive sulfhydril group, 
which is readily oxidized, makes it suited to a number of applications in ameliorating 
oxidative damage. In particular, such thiol-containing small molecules, such as D-
10 
Penicillamine, have been demonstrated to be highly effective quenchers of reactive 
aldehydes. Thus, the mechanism we propose as being most highly applicable to 
detoxification of atherosclerotic plaques is that of aldehyde quenching, whereby its 
sulfhydril group reacts directly with the aldehyde, forming thiazolidine derivatives which 
are nonreactive. 
Experimental Approach 
To test the efficacy ofMPG as a protective agent, we have used the following 
experimental model: Soft plaques obtained from carotid atheroma lesions are isolated 
and homogenized in ethanol. Murine-derived 1774 macrophage-like cells, which have 
been shown to respond to toxicity of atherosclerotic plaques44-46 , are exposed to varying 
concentrations of this homogenate, both with and without the addition of MPG. Standard 
culture viability assays are then used to determine the degree of protection conferred 
against plaque-induced cell death. 
11 
METHODS 
Plaque Homogenization - Type I Homogenate 
Samples of waste from percutaneous atherectomy procedures were obtained (IRB 
#286.07) from Dr. Timothy Godshall, MD at University Hospital in Louisville, KY. 
These were very dilute suspensions of atheroma lesion components suspended in saline. 
The saline suspensions were centrifuged at 20,000g for 30 minutes. The pellet was then 
weighed, suspended in 2ml 100% ethanol, and homogenized in a Wheaton glass-on-glass 
homogenizer. After one hour of homogenization, the plaque suspension was decanted 
off, and the remaining non-homogenizable components were weighed and then discarded. 
The suspension was further homogenized using the tightest-fitting rod for the 
homogenizer. After several hours of homogenization, the resulting suspension was added 
to additional ethanol to make a IOmg/ml stock suspension. 
Plaque Homogenization - Type II Homogenate 
Atheromatous plaque samples from carotid endarterectomy surgical waste were 
obtained immediately following procedures performed by Dr. Timothy Godshall, MD at 
University Hospital in Louisville, KY. The entire atheroma that had been removed in the 
endarterectomy was weighed after minimal drying to obtain the wet weight. This intact 
piece was placed in a glass-on-glass Wheaton homogenizer along with I-2ml of 100% 
ethanol, depending on the size of the atheroma. After one hour of homenization, the 
plaque suspension was decanted off, and the remaining non-homogenizable components 
12 
were weighed and then discarded. The suspension was further homogenized using the 
tightest-fitting rod for the homogenizer. After several hours of homogenization, the 
resulting suspension was added to additional ethanol to make a 5 to 100mg/ml stock 
suspension, depending on how much material was isolated. 
Plaque Homogenization - Type 111 Homogenate 
In an effort to isolate more gelatinous plaque from the carotid endarterectomy 
surgical waste samples without exposing other components to homogenization, the 
gelatinous plaque components were scraped off using a scalpel. The isolated material 
was then weighed and homomogenized as before, except no decanting/removal of non-
homogenizable material was necessary. We also attempted to maximize the 
concentration of our stock solutions, giving between 75 and 100mg/ml, depending on 
how m much material was isolated. 
Cell Culture 
1774 (Sigma #85011428) cells are derived from mouse monocyte/macrophage 
cells and form semi-adherent layers when cultured. Cells were cultured in Dulbecco's 
Modified Eagle's Medium (DMEM) with 2mM L-glutamine (Sigma #D6429) and 10% 
Fetal Bovine Serum (FBS) at 37°C in a CO2 incubator. 
Toxicity Assays 
24 or 96-well (24-well Costar Clear, Coming #3473, or 96-well Costar black w/ 
clear bottom, Coming #3603) plates were seeded between 10% and 50%, depending on 
the experiment, with 1774 cells and incubated at 37°C in a C02 incubator for 12h-24h, 
depending on the experiment, at which point plaque homogenate, hydrogen peroxide and 
MPG were added. Plates were then incubated for another 4h-24h, depending on the 
13 
experiment, at which time the medium was changed and replaced with fresh medium 
containing 10% AlamarBlue indicator. Following a 2h-4h incubation period, depending 
on the experiment, the plate was read with a spectrofluorometer to determine cell 
viability based on metabolic reduction of AlamarBlue. 
AlamarBlue Viability Assay 
AlamarBlue (ABD Serotec #BUF012B) was chosen because of its simplicity and 
reliability. A 10% solution of AlamarBlue in normal culture medium is added to cells, 
which under normal metabolic activity reduce the originally oxidized nonfluorescent blue 
form of the indicator to the reduced fluorescent red form. 4 hours usually falls within the 
linear phase of this reduction process, but readings at several different time points are 
taken to verify that the reading chosen is within this range. Quantitation via the 
spectrofluorometric plate reader ensures reliability and consistency. Viability is 
expressed as the percent reduction of the indicator in test groups vs. the percent reduction 
in controls. 
Clonogenic Expansion Viability Assay 
10cm polystyrene tissue culture 
plates were seeded with 200 cells each and 
incubated in DMEM at 37°C for 5 days. 
Medium was then removed, and plates were 
washed with phosphate-buffered saline 
(PBS). Cells were then fixed in a 50/50 
PMSlMethanol solution for 2 minutes, and 
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Figure 7 - Example marked-up image from colony formation assay. 
Stained and dried plates are filled with powdered sugar to provide 
contrast and minimize reflections off the side of the plate. The pencil 
tool in Adobe Photoshop was used to avoid miSSing or double--counting 
colonies. The 50px circle also provided a means of ensuring all counted 
colonies were above a certain size threshold. Counting was very fast, 
reliable and consistent across olates usina this method . 
Methanol was then removed, and the plates allowed to dry for 30 minutes. Cells were 
then stained with Gentian Violet stain for 30 minutes, rinsed with tap water, and allowed 
to air dry for 3 hours. Plates were then filled with powdered sugar to provide clean reads 
and scanned on an HP flatbed scanner. Colonies were then counted in Adobe Photos hop 
software, using the pencil tool with a 50pixel contrasting yellow circle to mark each 
colony (Figure 7), which ensured accuracy in counting and provided a consistent 
threshold for colony size. 
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RESULTS 
In order to verify plaque toxicity in our hands, a type I plaque homogenate (see 
Methods section above for details) was made from dilute plaque gruel samples (see 
Figure 8). The resulting homogenate was estimated to be 10mg/ml gruel, and 0.5% of 
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AlamarBlue, the fluorescence reading was taken . Results are expressed as a percentage of the 
viability of control cells, based upon the degree of AlamarBlue reduction . 
0.5% ethanol was used as a 
vehicle control. There were 24 
hours between seeding, adding 
toxins, and adding the 
AlamarBlue indicator. The 
plate was read 4 hours after 
AlamarBlue was added. 
Mostly due to the fact that the 
plate was too overgrown by the time the read was taken, not much toxicity could be seen, 
even with our lOOIlM H20 2 positive control. To address these issues, the next assay 
(Figure 9) was done using a 25% seeding density and more concentrated hydrogen 
peroxide, to be sure the positive control was showing up. This resulted in significant 
vehicle toxicity appearing from the ethanol, and virtual complete cell killing from the 
1mM hydrogen peroxide. 
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Plaque Toxicity 
As before, no significant 
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plaque toxicity apart from the 
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experiment was run (Figure 10) to 
reduce variability through more 
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Figure 9 - Plaque Toxicity Assay. A 24 well Costar plate was seeded at 25% confluence 
with J774 Cells. 24 hours later, plate was treated with 0.5% of the 10mg/ml plaque 
homogenate. 0.5% Ethanol as a vehicle control and 100 IJM H20 2 as a positive control. 
Six wells were used for each condition to provide replicates for improved statistical 
significance. 24 hours after that, medium was exchanged for new medium containing 
10% AlamarBluB. After 4h incubation with AlamarBlue, the fluorescence reading was 
taken. Results are expressed as a percentage of the viability of control cells, based upon 
the degree of AlamarBlue reduction. 
the result with higher ethanol and 
plaque concentrations. A 24 well 
Costar plate was seeded at 50% 
confluence with 1774 Cells. 24 hours later, the plate was treated with 1% of the 10mg/ml 
plaque homogenate. 1 % Ethanol as a vehicle control and 1000 /lM H20 2 as a positive 
control. Six wells were used for 
each condition to provide replicates 
for improved statistical 
significance. 24 hours after that, 
medium was exchanged for new 
medium containing 10% 
AlamarBlue. After 4h incubation 
with AlamarBlue, the fluorescence 
reading was taken. Toxicity was still 
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Figure 10 - Plaque Toxicity Assay. A 24 well Costar plate was seeded at 50% 
confluence with J774 Cells. 24 hours later, plate was treated with 0.5% of the 
10mg/ml plaque homogenate. 0.5% Ethanol as a vehicle oontrol and 1000 ~M H, O, 
as a positive control. Six wells were used for each condition to provide replicates for 
improved sta tistical significance. 24 hours after that, medium was exchanged for new 
medium containing 10% AlamarBlue. After 4h incubation with AlamarBlue , the 
fluorescence reading was taken. Results are expressed as a percentage of the 
viability of control cells, based upon the degree of AlamarBlue reduction. 
not very evident, but plate was quite overgrown by the time the reading was taken, again 
confounding the results. Interestingly, when the plate was subsequently left in the 
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MPG Toxicity 
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Figure 11· MPG Toxicity Assay. A 96-well plale was seeded at 10% 
confluence and allowed to incubate for 24h, at which point it was approximately 
20% confluent. MPG was added in various concentrations, ranging from 5mM 
to 150mM. Cells were incubated with MPG for 48h. and then a standard 
AlamarBlue assay was performed , with a reading taken after 4h incubation. 
Results are expressed as a percentage of the viability of control cells , based 
upon the degree of AlamarBlue reduction. 
incubator over the weekend, the cells in 
plaque-treated wells were completely 
detached, while ethanol and control 
wells were fine, containing an 
overgrown layer of cells. 
MPG and hydrogen peroxide 
toxicity assays (Figures 11 and 12) were 
done in order to find the appropriate 
levels for our model. In the case of 
MPG, we were looking for minimal toxicity. A 96-well plate was seeded at 10% 
confluence and allowed to incubate for 24h, at which point it was approximately 20% 
confluent. MPG was added in various concentrations, ranging from 5mM to 150mM 
(Figure 11). Cells were incubated with MPG for 48h, and then a standard AlamarBlue 
assay was performed, with a 
reading taken after 4h 
incubation. 5mM was 
completely non-toxic, while 
the higher concentrations all 
decreased viability somewhat. 
Based upon this finding, we 
chose 5mM as the ideal 
concentration for MPG. 
Hydrogen Peroxide Toxicity 
160 - 140 C; ... 
120 1: 








~~ e.' -<-0) ~ 0)<:> ~<:> 5::><:> 
0<:' ~q;: ~ ~ -<-'>< -<-OJ v 
Figure 12 - H20 2 Toxicity Assay. H20 2 was added to 25% confluent 24-well plates in pre-
diluted aliquots so 10~1 could be added to each well (wells contained 100~1 medium). 
Concentrations ranged from 9-900IJM. 1 QjJl water was added as a vehicle control . Then plates 
were incubated for 20h, when we changed medium to add 10% Alamar blue. Reading was 
taken 4 hours later. Results are expressed as a percentage of the viability of control cells, 
based upon the degree of AlamarBlue reduction. 
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Due to earlier problems in finding the appropriate H20 2 concentration for use as a 
positive control, an H20 2 toxicity assay was performed (Figure 12). H20 2 was added to 
25% confluent 24-well plates in pre-diluted aliquots so 101-1.1 could be added to each well 
(wells contained 1001-1.1 medium), 101-1.1 water was added as a vehicle control to detect 
possible effects from medium dilution. 24-well plates were used instead of 96-well so 
that H 20 2 could be pipetted directly into each well, to avoid earlier problems with 
depletion when using basins and a multichannel pipettor for the 96-well plates. 
Following addition of toxin, plates were incubated for 20h, at which time the 1774 cells 
were about 75% confluent in the most proliferative wells. Medium was then changed to 
add 10% Alamar blue. The reading was taken 4 hours later. Despite quite a bit of 
variability, an LDso of approximately 150l-l.M H20 2 was apparent. In subsequent 
experiments, we therefore used lOOI-l.M or 2001-tM, depending on the cell seeding density 
of the experiment at hand. 
Building on the experience gleaned from the previous assays, a larger scale 
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Figure 13 - MPG Experiment. 6 separate 96-well plates each contained a duplicate experiment. Results are from composite data from all 6 plates, 
representing 24 indivdual tests for each condition. Error bars represent 95% confidence intervals. 1% Ethanol was used as a vehicle and plaque 
concentrations of 5~9/ml through 50~9/ml were tested. Hydrogen Peroxide was 200~M . Results are expressed as a percentage of the viability of 
control cells, based upon the degree of AlamarBlue reduction. 
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experiment was done to test MPG alleviation of plaque toxicity using 6 96-well plates as 
replicates. Each plate contained a complete set of assays, with 4 wells being allotted to 
each condition (Figure 13). Fresh type II plaque homogenates were used (see Methods 
section above for details), and plates were seeded at 20% confluence. Unfortunately this 
still was not enough time, over the course of a 60+ hour experiment, to prevent the wells 
from becoming overgrown. Thus results were once again rather obfuscated. Despite 
these setbacks, due to the high number of replications a somewhat consistent trend could 
be seen where evident toxicity at lower plaque concentrations was alleviated by the 
addition ofMPG. Higher plaque concentrations proved inexplicably stimulatory to a 
certain degree, but MPG rescue, and even stimulation in the case of controls, could be 
seen across the board. 
In order to see more toxicity, (Figure 14), 96-well plates were seeded at 25% 
confluence, but a shorter overall time interval was used for the experiment. Three 























Figure 14 - 2.Sh Alamar Blue 96-well plates were seeded at 25% confluence. Three replicate plates were done, and plaque concentrations 
ranged from 25-100~g/ml. Hydrogen Peroxide was 200~M . 5mM MPG was added to groups labeled M. Results are expressed as a percentage 
of the viability of control cells , based upon the degree of AlamarBlue reduction. 
H20 2 was used due to anticipated depletion in the multipipette basin. Toxins were added 
just 8 hours after plate was seeded. If anything, wells treated with 5mM MPG fared 
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worse, possibly due to the 
short pre-incubation time. 
The apparent stimulatory 
effects of ethanol and plaque 
are not well understood. At 
the time the thinking was the 
plate was still too confluent, 
although the shorter-term 
Toxicity At Low Seeding Density 
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Figure 15 - 96-weU plates were seeded at 5% confluence. Cells were incubated with AlamarBlue 
for 3 hours before reading. Ethanol was 1 % Wells were seeded at 5% confluence, grown for 24 
hours and exposed to toxins for 48 hours. SmM MPG was added to groups labeled M. The MPG 
group represents control wells with MPG only added. Hydrogen Peroxide was 200~M . Results 
are expressed as a percentage of the viability of control cells. based upon the degree of 
AlamarBlue reduction . 
nature of the experiment (under 48h from seeding to read) was intended to alleviate that 
problem. 
The subsequent experiment (Figure 15) was done using an even lower seeding 
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Figure 16 - MPG Affect on Plaque Toxicity - 96-well plates were seeded at 10% confluence. Cells were 
incubated with AlamarBlue for 3 hours before reading. Ethanol was 1% Wells were seeded at 10% confluence, 
grown for 24 hours and exposed to toxins for 48 hours. SmM MPG was added to groups labeled M. Hydrogen 
Peroxide was 200~M . Results are expressed as a percentage of the viability of control cells, based upon the 
degree of AlamarBlue reduction. 
density in an attempt 
to get a picture of the 
longer-term effects on 
cell growth over two 
days, and to avoid the 
problems of wells 
getting overgrown 
before the assay was 
finished. Cells were 
incubated with AlamarBlue for 3 hours before reading. Ethanol was only 1 % Wells 
were seeded at 5% confluence, grown for 24 hours and exposed to toxins for 48 hours . 
Despite the fact that toxicity was clearly evident, even in the vehicle group, MPG still 
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apparently had no protective effect under this scenario. In fact, it seemed harmful, 
probably considering the smaller number of cells while MPG concentration remained at 
SmM. 
In order to strike a happy middle ground between too confluent and not confluent 
enough, we next seeded 3 96-well plates at 10% confluence, with a strict 24h regimen 
between seeding, adding toxins, and taking the reading (Figure 16). Another factor was 
new type III plaque homogenate (see Methods section above) . Unfortunately, the carotid 
endarterectomy samples made available at the time were particularly devoid of soft 
plaque components. Thus the samples extracted were extremely contaminated with 
material from the vessel wall due to excessive scraping. Thus, the Img/ml plaque 
concentration seems particularly intensive, yet actually reflects little plaque material. 
The apparent stimulatory effects in plate 1 are more than likely due to an abnormally low 
control group, due to problems with seeding density. 
In order to see why we were not getting hardly any plaque toxicity with the new 
samples, we performed two final assays 
- a colony formationlclonogenic 
expansion assay and a very rigorous 
AlamarBlue experiment using a 24-well 
plate. In the clonogenic assay (Figure 
17), we see stimulation at low plaque 
concentrations, deleterious effects at 
moderate-to-high doses. This 
Plaque Toxicity Clonogenic Assay 
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Figure 17 - 10cm polystyrene tissue culture plates were seeded with 200 cells 
each and incubated in DMEM at 3rC for 5 days. Cells were then stained with 
Gentian Violet stain for30 minutes. Plates were then scanned on an HP fl atbed 
scanner. Colonies were counted in Adobe Photoshop software, using the 
pencil tool with a SOpixel contrasting yellow circle to mark each colony. As 
wi th all assays, error bars represent 95% confidence intervals. 
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experimental system appears more sensitive than the AlamarBlue, which shows basically 
no effect in a straightforward plaque toxicity assay (Figure 18). 
Our fmal experiment was a test for plaque toxicity, using type III homogenates 
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Figure 18 - Plaque Toxicity using type III homogenates. Results are expressed 
as a percentage of the viability of control cells. based upon the degree of 
AlamarBlue reduction. Homogenate was 750~g/ml material - mostly non oxidized 
lipid. Results are expressed as a percentage of the viability of control cells. based 
upon the degree of AlamarBlue reduction. 
obtained from fresh samples, which 
were prepared immediately following 
collection from the OR. Cells were 
exposed to plaque approximately 1 hr 
after I left the OR with the sample, and 
the plate was seeded at 2xlO"S 
cells/ml, giving approx. 10% 
confluence for a 24-well plate. Wells 
were close to SO% confluence at the time the cells were exposed, and as the ethanol 
group shows, they were sufficiently resistant at this density. Sill of a 7Smg/ml 
homogenate was added to SOOIlI medium in the plaque group and Smcl ethanol for that 
group. Cells were exposed for 4 hours, treated with Alamarblue, then read 4h after that. 
These are the most optimal conditions we arrived at, judging from all of our previous 
experiments. The error bars outweigh the decreased viability, which is very slight to 
begin with. While not very exciting, this is consistent with the experiments completed up 
to this point. It seems like we have never been able to get decent toxicity out of the 
atherosclerotic material from carotid endarterectomies, and the very first experiments we 
did with more dilute samples were not much better. 
Overall, our impression is that with these experimental models, toxicity is so 
slight it gets buried in the noise with even the most doggedly consistent handling, unless 
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incredibly low seeding densities are used, at which point we have problems with vehicle 
and MPG toxicity. 
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DISCUSSION 
Prospects of This Approach 
After more than 10 experiments with this experimental system, its drawbacks are 
obvious; there is a very fine line between vehicle toxicity and overgrown plates, giving a 
very narrow (less than 48 hours) window of opportunity for experimentation. Therefore 
the prospects of this approach appear somewhat limited. This appears to be a mainly 
problem with the sample preparation, however. Variation in the samples procured, 
together with changes in composition due to handling seem to outweigh the toxic effects 
seen when oxidized lipids hit the plaque. The clonogenic assay seemed the most free 
from experimental artifacts, and was apparently exquisitely sensitive to even the slightest 
levels of growth stimulation and toxicity. Also, using extreme numbers of replicates, as 
in our most successful experiment (Figure 13) enables slight effects to stand out from the 
noise. Regardless, a new source of atheroma material is obviously necessary. In 
previous successful experiments46, 1.5g samples of purely soft plaque gruel were 
obtainable. Such a source would apparently be necessary in order for such experiments 
to succeed as they have done in the past, or better yet, artificially oxidized lipids. 
Complimentary Approaches 
Wang et al. have demonstrated the efficacy of using isolated LDL from plasma to 
create OxLDL using CUS04.44 Using such a reliable model for toxicity, in conjunction 
with an assay for cell viability that does not involve redox reactions such as Trypan blue 
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exclusion or Hoechst staining46 would probably be an excellent approach for future 
experimentation, especially for preliminary screening experiments such as these, 
although AlamarBlue seemed to work good enough in our hands for some of the 
experiments. Even more appropriately for drug candidate screens, an approach like that 
used by Wondrak et al. to use a screening method for direct, rapid detection of aldehyde 
quenchers 1 would be an effective first step at arriving at a few good compounds worthy 
of further testing. 
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CONCLUSION 
While our hypothesis remains somewhat in question, there have been some 
indications that MPG may be protective (Figure 13). Also there are obvious toxicity 
issues, depending on seeding density of the macrophages (Figures 14 and 15), so it by no 
means represents the quintessential aldehyde-quenching drug. Despite the shortcomings 
of this experimental approach however, the overall concept of using antioxidant and 
carbonyl-quenching therapy to treat atherosclerosis is on solid ground, and is still an 
active area ofresearch.47 Combination treatment with other therapies appears to be 
especially beneficial, both in regards to antioxidant therapi4,26,34 and conventional 
treatments with Statins and Omega-3 fattyacids48-51 . Thus, it seems that finding an 
effective aldehyde-quenching agent for additional combined treatment of 
atherosclerosis45,46 would go a long way towards the elimination of heart disease as the 
leading cause of death in developed countries. 
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